Time To Tip the Scales? Humira Biosimilars And The Limitations Of Competition In US Health Care

 
• By Sarah Karlin-Smith and Jinghong Chen

In year two, Humira biosimilar uptake – or the lack thereof – continues to build the case for policy reform to incentivize use of cheaper biologics in the outpatient setting.

road that splits in two directions with one direction leading toward "generic brand" and one direction leading toward "name brand"
Incentives in the US health care system make it hard for biosimilars to make inroads on brands used in the outpatient setting • Source: Shutterstock

AbbVie Inc.’s Humira lost 2% of market share to biosimilars in the US in 2023, the first year the blockbuster drug faced direct copycat competition.

More from Biosimilars

More from Biosimilars & Generics